NeuroSense Therapeutics Ltd. Warrant (NRSNW) Stock Price
NRSNWStock
$0.07
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta0.92
NRSNW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-99.20%
Price vs S&P 500 (4W)-46.64%
VGM Score29.50
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NRSNWNeuroSense Therapeutics Ltd. Warrant | — | — | D | $0.07 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About NeuroSense Therapeutics Ltd. Warrant
NeuroSense Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases including ALS, Alzheimer's, and Parkinson's disease. Its lead product candidate, PrimeC, is an extended-release oral formulation combining two FDA-approved generic drugs in a fixed-dose combination. The company aims to repurpose existing medications to address unmet needs in neurodegenerative disease treatment.